Glucagon like Peptide 1 News and Research

RSS

New trial tests strategies to protect heart health during prostate cancer therapy

City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened a phase 2 clinical trial comparing three different strategies for protecting heart health in prostate cancer patients who receive androgen deprivation therapy (ADT), a potentially lifesaving hormone therapy.

26 Jan 2026

Why exercise is essential for restoring fitness after GLP-1-based weight loss

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, improves physical function and cardiorespiratory fitness after diet-induced weight loss in adults with obesity. In contrast, liraglutide alone sustains weight loss but does not significantly improve measured physical fitness outcomes.

26 Jan 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

GLP-1 weight-loss drugs show early promise for treating addiction

This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders. Findings show consistent reductions in drug- and alcohol-seeking behaviors in animal models, while human evidence remains limited, heterogeneous, and preliminary.

21 Jan 2026

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin resistance.

21 Jan 2026

High-dose flu shots lower hospitalization risk in older adults

High-dose influenza vaccines may lower serious hospitalization rates in older adults, particularly those with diabetes, according to a recent Danish trial.

20 Jan 2026

Bariatric surgery reshapes body fat and muscle more than GLP-1 drugs

Bariatric surgery and GLP-1 treatments reshape body composition differently, emphasizing the importance of sex and treatment choice in muscle preservation.

14 Jan 2026

Most patients regain lost weight within two years of stopping obesity drugs

Weight management medications show limited long-term effects, with rapid weight regain post-treatment, emphasizing the need for sustainable obesity strategies.

13 Jan 2026

Why adherence determines weight loss success with semaglutide

Researchers examine how the effectiveness of weight-loss medications may depend on the patient adherence.

12 Jan 2026

Study highlights prevalence of GLP-1/GIP medication use for weight loss in UK

In early 2025, around 4.9 million British adults - almost one in ten - are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The findings, which are based on a nationally representative household survey of 5,260 British adults, are published in BMC Medicine.

8 Jan 2026

Weight loss drugs may cause nutritional deficiencies without proper guidance

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.

7 Jan 2026

Millions in Great Britain using or seeking weight loss drugs

An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according to a new study by UCL (University College London) researchers.

7 Jan 2026

Stopping weight loss drugs leads to rapid weight regain and health reversal

Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, finds a study published by The BMJ today.

7 Jan 2026

The gut is not just digestive and new evidence shows it actively controls brain function

This comprehensive review synthesizes a decade of human and animal research to explain how the gut and brain communicate through hormonal, neural, immune, and microbial pathways. It highlights how disruptions in these pathways contribute to gastrointestinal, metabolic, and neurological disorders, and how modern therapies are beginning to exploit gut–brain signaling for clinical benefit.

6 Jan 2026

Two isoforms of a cellular energy sensor play distinct, opposing roles in Alzheimer's disease

A comprehensive mini-review published today after peer review in Brain Medicine by Dr. Tao Ma and colleagues at Wake Forest University School of Medicine synthesizes emerging evidence that two isoforms of a critical cellular energy sensor play distinct, and sometimes opposing, roles in Alzheimer's disease.

6 Jan 2026

How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOS

This review synthesizes evidence that gut microbiota dysbiosis contributes to insulin resistance and symptom severity in polycystic ovary syndrome through impaired barrier function, inflammation, and altered microbial metabolites. It evaluates how Traditional Chinese Medicine may modulate these pathways while highlighting major gaps in clinical validation, safety, and standardization.

16 Dec 2025

Swapping high-carb snacks for tree nuts cuts food cravings in young adults at metabolic risk

Daily replacement of typical high-carbohydrate snacks with mixed tree nuts for 16 weeks reduced cravings for sweets and fast foods in young adults with early metabolic syndrome risk. This dietary swap improved overall diet quality, measured by the Healthy Eating Index, without increasing body weight or altering short-term glycaemic markers.

14 Dec 2025

Glucose-lowering drugs may reduce risk of developing epilepsy

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

In adults with stage IIIb–IV chronic kidney disease, the constipation drug lubiprostone did not reduce gut-derived uremic toxins but preserved creatinine-based kidney function over 24 weeks. The benefit was linked to microbiome remodeling, increased polyamine production, and improved mitochondrial function rather than toxin lowering.

8 Dec 2025

Glucagon like Peptide 1 News and Research

New trial tests strategies to protect heart health during prostate cancer therapy

Why exercise is essential for restoring fitness after GLP-1-based weight loss

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

GLP-1 weight-loss drugs show early promise for treating addiction

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

High-dose flu shots lower hospitalization risk in older adults

Bariatric surgery reshapes body fat and muscle more than GLP-1 drugs

Most patients regain lost weight within two years of stopping obesity drugs

Why adherence determines weight loss success with semaglutide

Study highlights prevalence of GLP-1/GIP medication use for weight loss in UK

Weight loss drugs may cause nutritional deficiencies without proper guidance

Millions in Great Britain using or seeking weight loss drugs

Stopping weight loss drugs leads to rapid weight regain and health reversal

The gut is not just digestive and new evidence shows it actively controls brain function

Two isoforms of a cellular energy sensor play distinct, opposing roles in Alzheimer's disease

How Traditional Chinese Medicine may reshape the gut microbiome to ease insulin resistance in PCOS

Swapping high-carb snacks for tree nuts cuts food cravings in young adults at metabolic risk

Glucose-lowering drugs may reduce risk of developing epilepsy

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Lubiprostone shows signs of slowing kidney function decline in chronic kidney disease

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News